Value Investing

Value Investing Articles

24/7 Wall St. has decided to do a bullish and bearish analysis for Wal-Mart and the rest of the DJIA components to see what lies ahead for 2015 and beyond.
Boeing still has a more positive analyst bias ahead for 2015, when compared to most other Dow Jones Industrial Average stocks.
One key consideration for the year ahead is that Disney will start to see the hype from the upcoming Star Wars franchise hit.
One key consideration for the year ahead for Caterpillar is that it was a surprise winner for much of 2014, before reality started to set in.
24/7 Wall St. has run a bullish and bearish review for Cisco to see what lies ahead for 2015 and beyond.
Many investors watch relative newcomer Goldman Sachs as a barometer of financials and banks. 24/7 Wall St. has run a bullish and bearish analysis on the firm.
One key consideration for the year ahead is that Nike enjoys a very powerful brand globally. It would not have been added to the Dow had that not been the case.
Coca-Cola stock underperformed the broader indexes in 2014, and analysts generally see another lackluster year for 2015. That being said, analysts are not always right.
The bull market is nearly six years old now, and some investors may be concerned that AT&T's stock is stuck in a long-term trading range at a time when growth looks elusive.
Exxon Mobil and Chevron have not yet revealed their proposed spending and production levels for this year, but they are also expected to spend less as low crude oil prices drag down profits.
24/7 Wall St. wanted to see which analyst picks in mid-cap to large-cap stocks offer the most upside. Some of these stocks still have very big upside targets on the surface.
24/7 Wall St. has compiled a group of the five best-performing utilities in 2014 that are cheap, on a price-to-earnings basis, going into 2015.
Credit Suisse updated its U.S. Focus List right before Christmas, and this is effectively the firm's highest conviction list for the year ahead.
A new report from Cowen breaks down in detail the metrics and earnings potential for all the major companies in the cleantech universe.
Out of 28 biotech stocks with market capitalization rates north of $300 million that were up 100% or more in 2014, seven of them were up 300% or more.